Published in Cancer Vaccine Week, April 5th, 2004
The DSMB recommended that CancerVax continue the trial as planned.
This recommendation means that, in the opinion of the DSMB, there is a reasonable likelihood that clinical endpoints can be met to establish the effectiveness of Canvaxin, and that there are no unexpected or serious toxicities associated with the product...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Vaccine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.